Market Overview

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

Share:

Allogene Therapeutics, Inc., a clinical-stage biotechnology company
pioneering the development of allogeneic CAR T therapies for cancer,
today announced the appointment of David M. Tillett, Ph.D., as Senior
Vice President, Head of Quality. In this role, Dr. Tillett will further
build Allogene's Quality system and oversee all Quality functions.

"I've had the privilege of working with Dave extensively and am thrilled
to have him officially join Allogene," said Alison Moore, Ph.D., Chief
Technical Officer of Allogene. "Dave is a proven technical leader with
vast experience in overseeing quality and CMC operations. As we continue
to progress our allogeneic CAR T cell portfolio, this deep understanding
will allow us to advance the CMC product quality and compliance
framework to help bring our engineered cell therapies to patients."

Dr. Tillett has over 25 years of experience in the production of
biological drug products, with expertise in process development,
manufacturing, and quality. Dr. Tillett previously served as President
of Berea Consulting, providing technical operations support to the
biotechnology and pharmaceutical industry. Dr. Tillett has also served
in multiple senior roles within Amgen, including Vice President of
Worldwide Quality. Prior to Amgen, he served in both manufacturing and
process development roles at Synergen and was a founder and
Vice-President of Sea Ag, a marine biotechnology company.

"My experience in cell therapy over the last three years, along with my
time at Allogene as a consultant, has only reinforced my belief that
allogeneic CAR T therapy has the potential to be the next step-change in
how people with cancer may be treated," said Dr. Tillett. "I look
forward to building and overseeing the quality function and being a part
of this exciting time at Allogene."

Dr. Tillett received a B.S.Ch.E. in chemical engineering from the
University of Delaware, and an M.S.Ch.E. and a Ph.D. in chemical
engineering from the Georgia Institute of Technology.

Allogene is advancing its allogeneic CAR T cell portfolio acquired from
Pfizer, which includes rights to 16 preclinical CAR T cell therapy
targets licensed from Cellectis and Servier and U.S. rights to UCART19,
an allogeneic CAR T cell therapy candidate that is being developed for
the treatment of CD19-expressing hematological malignancies. In
partnership with Servier, UCART19 is in Phase 1 development for the
treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

About Allogene Therapeutics

Allogene Therapeutics is a clinical stage biotechnology company
pioneering the development of allogeneic chimeric antigen receptor
T-cell (CAR T) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is developing
a pipeline of "off-the-shelf" CAR T cell therapy candidates with the
goal of delivering readily available cell therapy faster, more reliably
and at greater scale to more patients.

Allogeneic CAR T cell therapies are engineered from cells of healthy
donors which is intended to allow for creation of inventory for
"off-the-shelf" use in patients. This approach is designed to eliminate
the need to create personalized therapy from a patient's own cells,
simplify manufacturing, and reduce the time patients must wait for CAR T
cell treatment. The Allogene portfolio includes rights to 16
pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T
therapy candidate currently in Phase 1 development for the treatment of
relapsed/refractory acute lymphoblastic leukemia (ALL).

Through its notable partnerships, Allogene leverages pioneering
technology platforms, including TALEN® gene-editing
technology from Cellectis, to progress its portfolio of CAR T cell
therapies. Allogene, with headquarters in South San Francisco,
California, is a Two River portfolio company formed with one of the
largest Series A financings in biotechnology from an investment
consortium that includes TPG, Vida Ventures, BellCo Capital, the
University of California Office of the Chief Investment Officer, Gilead
and Pfizer. For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.

View Comments and Join the Discussion!